Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 8/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636459 | 0.86 | CHRNA7 (0.44) | UGCGCHRNA7HTR3ARBP4ALDH1A1 | |
| SCHEMBL1635365 | 0.79 | TNKS (0.37) | UGCGCHRNA7HTR3ARBP4ALDH1A1 | |
| SCHEMBL1636659 | 0.77 | QPCT (0.44) | UGCGHTR3A | |
| SCHEMBL2848192 | 0.77 | MEN1 (0.54) | DDB1CRBNRBP4 | |
| SCHEMBL4529923 | 0.74 | CCNC (0.42) | UGCGCHRNA7HTR3ARBP4MAPK1 | |
| SCHEMBL492824 | 0.73 | CHRNA7 (0.53) | CHRNA7HTR3A | |
| Formic Acid SCHEMBL1572911 | 0.71 | CCNC (0.39) | UGCGCHRNA7HTR3ARBP4MAPK1 | |
| SCHEMBL1636745 | 0.71 | UGCG (0.48) | UGCGCHRNA7HTR3ARBP4 | |
| SCHEMBL1177183 | 0.70 | HTR3A (0.41) | DDB1CRBNHTR3ARBP4ALDH1A1 | |
| SCHEMBL2844631 | 0.70 | KDM4E (0.46) | DDB1CRBNHTR3AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932248-B2 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| EP-1963332-A1 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070135417-A1 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | MEMORY PHARMACEUTICALS CORPORATION | 2007-06-14 | — | — | US | disclosed |
| WO-2007056582-A1 | 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135417-A1 | 3-(1,4-Diazabicyclo[3.2.2]non-4-ylcarbonyl)-5-(tetrahydro-2H-pyran-4-yloxy)-1H-indazole,nicotinic receptor agonists; particularly ligands for the nicotinic alpha-7-receptor(alpha 7 nAChR subtype); brain disorders; neuroprotectants; strokes; antiischemic agents; glutamate-induced excitotoxicity | CHRNA7, CHRNA5, CHRNA3 | UGCG 3702/4885DDB1 1928/4885CRBN 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.